EUVIMEDEUVIMED entdecken
Crossref

Hereditary breast and ovarian cancer genetic testing in unselected patients: example of private supplementation of public healthcare service

Francesca Fiorentino, Giovanni Innella, Federica Balducci, Laura Marullo, Giulia Lanzoni, Sara Miccoli, Laura Cardarelli, Daniela Turchetti, Sergio Tempesta

Familial Cancer · 2025

DOI: 10.1007/s10689-024-00426-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Familial Cancer, 2025. Verfasst von Francesca Fiorentino und 8 weiteren Autor:innen. Beteiligte Einrichtung: Cerba HealthCare Emilia-Romagna, Bologna, Italy. Hauptthemen laut MEDLINE: Genetic Testing, Checkpoint Kinase 2, BRCA2 Protein, Ovarian Neoplasms. Die Arbeit nennt 11 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the Emilia-Romagna region (Northern Italy), the identification and management of women at familial/hereditary risk of breast and ovarian cancer is guided by a well-established regional protocol. Here we report the results of the experience of private supplementation of public healthcare service in offering the possibility to undergo BRCA1/2 testing and/or multigene panel testing (MGPT) within a well-defined pathway to women unfulfilling regional criteria. Out of 177 patients referred to our center who underwent BRCA1/2 testing, 175 tested negative while two (1.1%) resulted carriers of pathogenic variants in BRCA2; 69 patients also underwent MGPT, and in four cases (5.8%) a pathogenic variant were found (two in ATM and one in CHEK2 and RAD51C, respectively). Overall, this private supplementation of territorial public healthcare system has made it possible to confirm the validity of regional criteria for genetic testing access (concordance: 98.9%), but also to identify carriers of pathogenic variants of BRCA1/2 that would have escaped regional protocol, to support the effectiveness of MGPT for the identification of rare cases (not BRCA) at mild/high risk, and to provide reassurance to women who were found to be non-carriers of pathogenic variants, who may benefit from a more accurate assessment of their risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic TestingCheckpoint Kinase 2BRCA2 ProteinOvarian NeoplasmsHumansFemaleMiddle AgedAdultAgedBreast NeoplasmsBRCA1 ProteinItalyGenetic Predisposition to DiseaseAtaxia Telangiectasia Mutated ProteinsHereditary Breast and Ovarian Cancer SyndromeDNA-Binding Proteins

Stichwörter der Autor:innen

BRCA1BRCA2Breast cancerOvarian cancer

Substanzen

CHEK2 protein, humanCheckpoint Kinase 2BRCA2 ProteinBRCA2 protein, humanBRCA1 protein, humanBRCA1 ProteinRAD51C protein, humanAtaxia Telangiectasia Mutated ProteinsATM protein, humanDNA-Binding Proteins

Autor:innen und Institutionen

  • Cerba HealthCare Emilia-Romagna, Bologna, Italy.
  • Cerba HealthCare Lombardia, Milan, Italy.
  • Department of Medical and Surgical Sciences, Center for Studies on Hereditary Cancer, University of Bologna, Bologna, Italy.
  • Medical Genetics Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Cerba HealthCare RDI, Limena, PD, Italy.
  • Cerba HealthCare Campania, Naples, Italy.

Zitieren

APA

Fiorentino, F., Innella, G., Balducci, F., Marullo, L., Lanzoni, G., Miccoli, S., Cardarelli, L., Turchetti, D., & Tempesta, S. (2025). Hereditary breast and ovarian cancer genetic testing in unselected patients: example of private supplementation of public healthcare service. Familial Cancer. https://doi.org/10.1007/s10689-024-00426-8

Vancouver

Fiorentino F, Innella G, Balducci F, Marullo L, Lanzoni G, Miccoli S, et al. Hereditary breast and ovarian cancer genetic testing in unselected patients: example of private supplementation of public healthcare service. Familial Cancer. 2025. doi:10.1007/s10689-024-00426-8

BibTeX
@article{Fiorentino2025,
  author = {Fiorentino, Francesca and Innella, Giovanni and Balducci, Federica and Marullo, Laura and Lanzoni, Giulia and Miccoli, Sara and Cardarelli, Laura and Turchetti, Daniela and Tempesta, Sergio},
  title = {Hereditary breast and ovarian cancer genetic testing in unselected patients: example of private supplementation of public healthcare service},
  journal = {Familial Cancer},
  year = {2025},
  doi = {10.1007/s10689-024-00426-8}
}
Kostenlos starten →